Genomic Health, Inc. (NASDAQ:GHDX) tinted loss of -1.18% (-0.6 points) to US$50.1. The volume of 0.28 Million shares climbed down over an trading activity of 203 Million shares. EPS ratio determined by looking at last 12 month figures is -0.2. Over the same time span, the stock marked US$53.65 as its best level and the lowest price reached was US$26.54. The corporation has a market cap of US$1.76 Billion.

Genomic Health, Inc. (NASDAQ:GHDX)’s earnings per share has been growing at a -19.5 percent rate over the past 5 year when average revenue increase was noted as 7.7 percent. The return on equity ratio or ROE stands at -3.7 percent while most common profitability ratio return on investment (ROI) was -4.2 percent. The company’s institutional ownership is monitored at 91.4 percent. The company’s net profit margin has achieved the current level of -2 percent and possesses 82.9 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 5 think it is Hold. Recently, analysts have updated the overall rating to 2.78. 0 analysts recommended Overweight these shares while 2 recommended Underweight, according to FactSet data.

Braskem S.A. (NYSE:BAK) is worth US$9.1 Billion and has recently fallen -1.19% to US$22.48. The latest exchange of 0.3 Million shares is below its average trading activity of 360.31 Million shares. The day began at US$22.8 but the price moved to US$22.29 at one point during the trading and finally capitulating to a session high of US$22.82. The stock tapped a 52-week high of US$33.73 while the mean 12-month price target for the shares is US$33.75.

Currently, the stock carries a price to earnings ratio of 10.34, a price to book ratio of 4.31, and a price to sales ratio of 0.7. For the past 5 years, the company’s revenue has grown 6.4%, while the company’s earnings per share has grown 43.2%. With an institutional ownership near 12.6%, it carries an earnings per share ratio of 2.17.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.67.